Gilead’s Kite presents new analysis on second-line Yescarta therapy

Kite, a Gilead (GILD) Company, presented a new analysis demonstrating that second-line Yescarta therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma, even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant, ASCT. Results were shared from the combined analysis of four-year data from the landmark ZUMA-7 Phase 3 pivotal study of Yescarta for R/R LBCL and two-year data from the Phase 2 ALYCANTE study, designed by French collaborative group LYSA and sponsored by LYSARC, for transplant-ineligible patients. The findings were presented during the 67th American Society of Hematology, ASH, Annual Meeting and Exposition. After two years: Overall survival rate, meaning the percentage of patients in the trials who were still alive, was 64.9% in the pooled analysis, 62.8% in ZUMA-7, and 70.8% in ALYCANTE. Event-free survival rate, meaning the percentage of patients who were still alive and had not seen their disease worsen or experienced other major complications, was 45.2% in the pooled analysis, 45.4% in ZUMA-7, and 44.7% in ALYCANTE. Additionally: After three months, 55.6% of the patients in the pooled analysis showed a complete metabolic response, meaning their disease was barely, if at all, detectable. CMR was 51.2% in ZUMA-7 and 67.7% in ALYCANTE. After one year after treatment, overall response rate, meaning patients saw their cancer significantly shrink or completely disappear, was 46.6% in the pooled analysis, 46.5% in ZUMA-7, and 46.8% in ALYCANTE.